JVJonathan Valabhji

Jonathan Valabhji

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jonathan Valabhji has a total of 509 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real-world evidence for decisions in diabetes

    by Shivani Misra, Monika Cigler, Omaima El-Hakouni, Martina Vettoretti, Enrico Longato, Jonah Thomas, Christian Torp-Pederson, Jonathan Valabhji, Amanda Adler, Bastiaan de Galan, et al.

  • Open Access

    Implementation and Phase 1 evaluation outcomes of the NHS England National Diabetes Transition and Young Adult Pilot Programme (2022–2026)

    by Reza Zaidi, Fulya Mehta, Partha Kar, Jonathan Valabhji, Verity Hawkes, Lucy Holmes, Karen Kennedy, Sheena Dungey, Mo Jaffer Ismail

    Aims: This programme was a 4‐year, centrally commissioned endeavour to gather evidence of strategies to implement a model service specification in 15 pilot sites and improve outcomes in 16‐ to 25‐year‐olds with diabetes. Methods: Retrospective cohort study evaluating the quantitative and qualitative impact of implementing the model service specification on the study population. Phase 1 focused on changes and outcomes between 2022 and 2024. Results: Services implemented changes to improve engagement, well‐being, care process measurements and clinical outcomes. 6564 individuals' data were analysed across sites. At the end of 2024, caseloads increased by 15% for type 1 diabetes (T1D) and 64% for type 2 diabetes (T2D). Young adult multidisciplinary team appointments offered ( 2022 : 5168, 2024 : 9013) and attended (67.5% in 2024 vs. 64.1% in 2022, p < 0.001) surged, and non‐attendance rates reduced (20.2% vs. 27.8%, p < 0.001). Measurements of HbA1c (73.2% vs. 69%, p < 0.01), blood pressure (69.1% vs. 57%, p < 0.0001), BMI (67.8% vs. 57%, p < 0.0001), psychological screening (43.8% vs. 14.7%, p < 0.0001) and uptake of hybrid closed loop systems increased. Median HbA1c reduced for the entire cohort (3 mmol/mol or 0.3%, p < 0.0001 for T1D, 4 mmol/mol or 0.4%, p = 0.2 for T2D). Treatment target achievement for HbA1c (T1D: 39.1%, p < 0.0001, T2D: 52.8%, p = 0.2) and blood pressure (T1D: 84.6%, p < 0.01, T2D: 74.1%, p = 0.3) increased. DKA admission rate (13.8 vs. 16.4, p < 0.05), hospital bed‐days (42.1 to 30.1, p < 0.0001) and length of stay (2.57 to 2.18) reduced, with financial savings of £10,000/100 young people. Improved well‐being was also reported. Conclusion: Early evaluation of the programme has shown improved outcomes for young people.

  • Open Access

    Real‐World Databases in Diabetes: A Systematic Review

    by Jonah J. C. Thomas, Anna Meffen, Alessandro Rizzi, Andrew P. Kingsnorth, Beatrice Pieri, Ying He, Shirley Konnor, Clare Gillies, Kamlesh Khunti, Jonathan Valabhji, et al.

    Aim: To identify publications that describe RWD databases in the field of diabetes and map their key characteristics. Methods: Databases were searched (MEDLINE, SCOPUS, CINAHL from January 2018 to October 2025) to identify relevant publications describing RWD databases. Eligible studies were identified as RWD databases that contained more than 1000 adults and were followed up for one year or longer. Metadata including population, sample size, and outcomes were then extracted. Results: A total of 610 eligible RWD databases were identified from 1779 included articles. Databases were identified in 74 countries, with the majority collected in Europe ( n = 193). Only 22 databases were identified in lower‐ and‐ middle income countries (as defined by the World Bank). Demographics, prescription, diagnosis, and biochemical information were collected frequently; however, mortality and technology related variables (CGM usage) were found in fewer datasets. Very few databases were open access however 205 mentioned having the possibility for data sharing. Conclusion: We have produced an online dashboard to summarise the RWD databases available in the field of diabetes. We found many RWD databases globally that contain a range of variables related to individuals' health; however, lower‐ and middle‐income nations are underrepresented within these data.

  • Open Access

    Trends in type 2 diabetes incidence and BMI at diagnosis by age, sex, and ethnicity, 2011–2024: a population-based analysis of the English National Diabetes Audit

    by Naomi Holman, Jackie O’KEefe, Edward Gregg, Garry Daniel Tan, Kamlesh Khunti, Jonathan Valabhji, Chirag Bakhai, Clare Hambling, Bob Young, Shivani Misra


  • Top Cited Papers

    Interventions for the prevention and management of cardiometabolic multiple long-term conditions

    by Jonathan Valabhji, David Hope, Nuha El Sayed, Pamela Miloya Godia, Claire Lawson, Samuel Seidu, Kamlesh Khunti


  • Diabetic peripheral neuropathy: the broader complication burden

    by Jonathan Valabhji, Aikaterini Theodoraki, David Hope

    Effective care requires a holistic approach to account for diverse disease manifestations


  • Open Access

    Banting memorial lecture 2025: Aligning clinical practice, policy and research

    by Jonathan Valabhji

    National clinical leadership, on a background of clinical practice and clinical research, provides unique perspectives. I have focused the Banting Memorial Lecture 2025 on the implementation of national programmes across England since 2013, for which, along with colleagues at NHS England, I successfully made the case for investment, led the implementation of interventions applied at scale across the country and used routinely collected healthcare data to demonstrate clinical effectiveness in the real world. Through specific examples of implemented programmes, including the NHS Diabetes Prevention Programme and the NHS Type 2 Diabetes Path to Remission Programme, I highlight important fundamental principles when making the case for, and implementing, national policy. First, ensure granular data collection to support evaluation and exploit data linkages to harness the power of real‐world datasets. Second, where good evidence exists, implement evidence‐based policy; where good evidence does not exist but political pressures to implement are being brought to bear, pilot and evaluate. Third, when the opportunity arises, rapidly translate new high‐quality evidence into policy and practice. And fourth, support and protect the workload of healthcare professionals, particularly of those working in primary care. Then, through an epidemiological lens, I highlight: how the COVID‐19 pandemic further unlocked the potential of national routinely collected electronic healthcare datasets; how, through application of these datasets, it has been possible to demonstrate improvements in diabetes complications and mortality through routine care delivery; and how it has been possible to demonstrate the next epidemiological transition in the global diabetes epidemic to multimorbidity/multiple long‐term conditions.


  • Open Access

    Evaluating a digital intervention for prevention of type 2 diabetes: protocol for a cluster-randomised controlled trial in urban and rural India

    by Parizad Avari, Harish Ranjani, Sharma Nitika, Narayanaswamy Jagannathan, Viswanathan Mohan, Ashutosh Yadav, Menka Loomba, Akansha Tyagi, Nick Oliver, Vinitaa Jha, et al.

    Background: The rising prevalence of diabetes, particularly in low- and middle-income countries, highlights an urgent need for innovative approaches to prevention. India faces a growing burden of type 2 diabetes (T2D), placing considerable strain on affected individuals and healthcare systems. This study aims to evaluate the effectiveness of a digital intervention designed to prevent T2D in individuals with pre-diabetes in India. Methods: A total of 3,240 individuals with pre-diabetes will be recruited across urban and rural settings in Tamil Nadu and Delhi. Participants will be cluster randomised to either the digital intervention group or the control group (usual standard of care). Clusters will comprise of wards in urban areas and villages in rural areas. Initial screening will be conducted using the Indian Diabetes Risk Score (IDRS) ≥ 30 and/or a random capillary blood glucose level ≥ 110 mg/dL. Final recruitment into the study will be based on capillary oral glucose tolerance testing (OGTT) and/or HbA1c levels. The primary outcome is incidence of T2D at 24 months, and secondary outcomes are cardiometabolic events, lifestyle and behavioural factors, and cost effectiveness of digital interventions. The study is registered with the Central Trials Registry of India (CTRI/2022/02/040650). Discussion: This protocol paper details the comprehensive study design aimed at evaluating the effectiveness of a digital intervention to prevent T2D in India. If effective, the study will provide important insights into the use of technology in resource-constrained settings and offer a scalable solution for diabetes prevention. The findings could also inform future interventions and policies aimed at curbing the rising burden of diabetes in low- and middle-income countries. Trial registration: CTRI/2022/02/040650 (registration date: 28.02.2022). https://ctri.nic.in/Clinicaltrials/pmaindet2.php?EncHid=NjE2NzE=&Enc=&userName=

  • Open Access

    Association between the English National Health Service Diabetes Prevention Programme and incident multiple long-term conditions

    by Emma Barron, Paul Chappell, Izzy Hatfield, David C. D. Hope, Xiaochen Ge, Chirag Bakhai, Dominique Bradley, Ellie Bragan Turner, Rupert Dunbar-Rees, Nasrin Hafezparast, et al.

    Existing evaluations of the National Health Service Diabetes Prevention Programme (NHS DPP) in England have demonstrated associated reductions in body weight, hemoglobin A1c and incident type 2 diabetes (T2D). In this study, we examined associations between completion of the NHS DPP and incidence of T2D and 30 other long-term conditions (LTCs), including LTCs considered linked to the programʼs interventional goals of body weight reduction, increased physical activity and improved diet quality (LTC-L) and LTCs considered to be possibly linked to those goals (LTC-PL). We found that completers of the NHS DPP had lower incidences of T2D, LTC-L and LTC-PL compared to non-attenders. Although these associations attenuated over time, they remained significant for all outcomes at 24 months with an odds ratio of 0.53 (95% confidence interval: 0.48–0.59) for T2D and rate ratios of 0.79 (0.74–0.84) and 0.80 (0.74–0.88) for LTC-L and LTC-PL, respectively. However, we were not able to directly conclude whether lower incidence rates were a direct result of completing the NHS DPP or due to residual bias stemming from unmeasured confounding and imprecision in the estimation of diagnosis.